Brokerages Expect Sutro Biopharma Inc (STRO) Will Post Earnings of -$0.56 Per Share
Brokerages expect Sutro Biopharma Inc (NASDAQ:STRO) to post earnings per share (EPS) of ($0.56) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Sutro Biopharma’s earnings. The lowest EPS estimate is ($0.62) and the highest is ($0.51). The firm is scheduled to announce its next earnings results on Monday, July 1st.
On average, analysts expect that Sutro Biopharma will report full-year earnings of ($2.15) per share for the current fiscal year, with EPS estimates ranging from ($2.58) to ($1.69). For the next fiscal year, analysts anticipate that the firm will post earnings of ($2.62) per share, with EPS estimates ranging from ($3.26) to ($2.28). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Sutro Biopharma.
STRO has been the subject of a number of analyst reports. Zacks Investment Research lowered Sutro Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, January 17th. Wedbush raised their target price on Sutro Biopharma from $20.00 to $22.00 and gave the company an “outperform” rating in a research report on Monday, March 4th. Finally, ValuEngine lowered Sutro Biopharma from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $24.33.
NASDAQ STRO traded down $0.09 on Wednesday, reaching $11.00. The company had a trading volume of 1,214 shares, compared to its average volume of 25,828. The firm has a market capitalization of $257.91 million and a P/E ratio of -1.79. Sutro Biopharma has a 52-week low of $8.50 and a 52-week high of $15.90.
Sutro Biopharma Company Profile
Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
Further Reading: Percentage Decliners
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.